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Résumé 
 
 
 
Afin d’apporter la preuve directe que les interneurones répondant aux tachykinines 
peuvent établir des connections monosynaptiques avec les cellules pyramidales, 
nous avons réalisé des enregistrements simultanés de paires d’interneurone/cellule 
pyramidale. Dans les paires connectées, le peptide provoquait une décharge de 
potentiels d’action dans l’interneurone et, de façon concomitante, engendrait une 
augmentation des CPSIs dans la cellule pyramidale. Dans les paires non 
connectées, nous n’avons pas mis en évidence, en présence du peptide, une 
activation de synapses inhibitrices « silencieuses ».  
 
Nous avons aussi démontré que l’activation d’interneurones par les tachykinines 
pouvait indirectement inhiber d’autres interneurones. Nous avons pu montrer que 
cet effet était dû à des récepteurs de type NK1.  
 
Nous concluons que les tachykinines peuvent influencer le fonctionnement de 
l’hippocampe en inhibant indirectement les cellules pyramidales mais aussi d’autres 
interneurones inhibiteurs. Selon la balance précise entre ces effets, les tachykinines 
peuvent promouvoir soit l’activation, soit la dépression de l’hippocampe. 
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I. Préambule  
Le travail présenté ici a été effectué parallèlement à un travail de doctorat ès Sciences, 
mention biologique, dans le cadre d’un programme MD-PhD. Les données rapportées dans 
ce travail – à l’origine d’un manuscrit à soumettre à l’European Journal of Neuroscience –   
constituent  la suite du travail consacré à l’hippocampe et aux tachykinines : 
 
R. Ogier and M. Raggenbass  
Action of tachykinins in the rat hippocampus: modulation of inhibitory synaptic transmission. 
European Journal of Neuroscience, Vol 17, pp. 2639-2647, 2003 
 
 
Les autres articles écrits dans le cadre du programme MD-PhD et incorporés dans la thèse 
de doctorat ès Sciences sont les suivants :  
 
X. Liu, E. Tribollet, R. Ogier, C. Barberis and M. Raggenbass  
Presence of functional vasopressin receptors in spinal ventral horn neurons of young rats : a 
morphological and electrophysiological study. 
European Journal of Neuroscience, Vol. 17, pp. 1833-1846, 2003 
 
R. Ogier, X. Liu, E. Tribollet, M. Raggenbass and D. Bertrand 
Identified spinal motoneurones of young rats possess nicotinic acetylcholine receptors of the 
heteromeric family. 
European Journal of Neuroscience, Vol 20, pp. 2591-2597, 2004 
 
R. Hurst, M. Hajós, M. Raggenbass, T. Wall, N. Higdon  J. Lawson, K. Rutherford-Root, M. 
Berkenpas, W. Hoffmann, D. Piotrowski, V. Groppi, G. Allaman, R. Ogier, S. Bertrand, D. Bertrand, 
and S. Arneric  
A Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic Acetylcholine Receptor: In 
Vitro and In Vivo Characterization 
Journal of Neuroscience, April 25, 2005 - 25(17): 4396-4405 
 
Eric Charpentier, Andreas Wiesner, Kyung-Hye Huh, Geraldine Allaman, Roch Ogier, Mario 
Raggenbass, Dominik Feuerbach, Daniel Bertrand and Christian Fuhrer  
α7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine 
phosphorylation and Src-family kinases 
Journal of Neuroscience, October 26, 2005 – 25(43):9836-9849 
 
R. Ogier, E. Tribollet, D. Bertrand and M. Raggenbass  
Identified motoneurons involved in sexual and eliminative functions in the rat are powerfully 
excited by vasopressin and tachykinins 
Journal of Neuroscience, October 18, 2006 – 26(42) :10717-10726 
 
 
 
II. Résumé en français  
Dans ce travail, nous nous sommes intéressés à l’action d’une famille de neuropeptides 
dans le système nerveux central. Depuis 25 ans, il est apparu que de nombreux peptides, 
connus principalement pour leurs activités périphériques, pouvaient aussi agir comme 
messagers au niveau du système nerveux central. Les neuropeptides sont constitués de 3 à 
100 acides aminés et sont jusqu’à 50 fois plus grands que les neurotransmetteurs 
classiques. Ils contiennent plus d’informations chimiques et de sites de reconnaissance pour 
les récepteurs que les neurotransmetteurs. Par conséquence, l’affinité de liaison des 
neuropeptides est environ 1000 fois plus élevée que celle des neurotransmetteurs, leur 
sélectivité est plus grande et le nombre de copies devant être relâchées par un neurone est 
plus petit. Les neuropeptides diffusent et se lient plus lentement mais plus fermement aux 
récepteurs que les neurotransmetteurs classiques. Presque tous les neuropeptides sont 
présents dans un neurone en combinaison avec un voire deux neurotransmetteurs. Cela 
permet une communication synaptique rapide (2-5ms) et lente (100-500ms). Le relâchement 
des neuropeptides nécessite une fréquence de décharge plus élevée, mais, une fois libérés, 
ces derniers peuvent atteindre des récepteurs situés loin du site de relâchement.  
 
La substance P (SP) fut, en 1931, le premier peptide identifié comme ayant une activité sur 
des récepteurs périphériques. Injecté de façon systémique, ce peptide causait des 
hypotensions transitoires et des contractions de tissu intestinal in vitro. Le terme 
« substance P » vient du fait que la substance active était extraite de cerveau et d’intestin 
de cheval et se présentait sous la forme d’une poudre (d’où le P). La SP appartient à la 
famille des tachykinines qui comprend notamment la neurokinine A, la neurokinine B et les 
neuropeptides γ et K. Ces peptides ont en commun la partie C-terminale suivante : Phe-X-
Gly-Leu-Met-NH2. Les récepteurs aux tachykinines sont classés en 3 sous-types, NK1, NK2 
 
 
et NK3 selon qu’ils lient de façon préférentielle la SP, la neurokinine A ou la neurokinine B 
respectivement. Dans le système nerveux central, les récepteurs aux tachykinines sont 
impliqués dans de nombreuses fonctions de régulation. Ils jouent notamment un rôle dans la 
transmission de la douleur au niveau de la moelle et dans la régulation du système 
cardiovasculaire et pulmonaire au niveau du tronc cérébral. Les récepteurs aux tachykinines 
situés dans l’amygdale et les aires cérébrales qui lui sont associées participent 
probablement à la genèse de l’anxiété et de la dépression. 
 
Dans un premier travail (Ogier et Raggenbass, 2003), nous avons démontré qu’en excitant 
ces interneurones, les tachykinines peuvent inhiber de façon indirecte les cellules 
pyramidales de cette région. Les tachykinines diminuent l’intervalle entre les courants post-
synaptiques inhibiteurs (CPSIs) et augmentent l’amplitude de ces courants dans presque 
toutes les cellules pyramidales testées. Cet effet est aboli par la tétrodotoxine, un bloqueur 
des potentiels d’action, ce qui suggère un effet présynaptique sur le soma ou les dendrites 
des interneurones, plutôt que sur leurs terminaisons axonales. L’effet de la substance P sur 
les CPSIs est reproduit par un agoniste des récepteurs NK1 mais pas par des agonistes des 
récepteurs NK2 ou NK3. Il est par ailleurs aboli par un antagoniste du récepteur NK1. Nous 
concluons donc que l’effet de la substance P est dû à l’activation d’un récepteur aux 
tachykinines de type NK1. 
 
Dans les interneurones du stratum radiatum de l’hippocampe, la substance P génère un 
courant entrant, résistant à la tétrodotoxine, ou provoque une dépolarisation souvent 
accompagnée de potentiels d’action. Cet effet direct est dû à des récepteurs de type NK1. 
Nous avons aussi réalisé des courbes courant-voltage qui indiquent que le courant net 
généré par les tachykinines inverse sa polarité proche du potentiel d’équilibre du potassium, 
 
 
suggérant que la suppression d’une conductance potassique de repos pourrait être à 
l’origine de l’effet observé. 
 
En augmentant l’excitabilité des interneurones GABAergiques du CA1, les tachykinines 
peuvent augmenter l’input inhibiteur sur les cellules pyramidales. Cette inhibition indirecte 
pourrait jouer un rôle dans la régulation de la plasticité synaptique à court et long terme, 
promouvoir la synchronisation des circuits neuronaux ou encore influencer la genèse de 
crises d’épilepsie. 
 
Dans la première partie de ce travail, afin d’apporter la preuve directe que les interneurones 
répondant aux tachykinines peuvent établir des connections monosynaptiques avec les 
cellules pyramidales, nous avons réalisé des enregistrements simultanés, en configuration 
whole-cell, de paires d’interneurone/cellule pyramidale. Deux des 15 paires enregistrées 
étaient connectées synaptiquement. L’effet de la substance P a été testé sur l’une d’elles. 
Le peptide provoquait une décharge de potentiels d’action dans l’interneurone et, de façon 
concomitante, engendrait une augmentation des CPSIs dans la cellule pyramidale. Dans les 
paires non connectées, nous n’avons pas mis en évidence, en présence du peptide, une 
activation de synapses inhibitrices « silencieuses ».  
 
Dans une deuxième partie de ce travail, nous avons déterminé si l’activation d’interneurones 
par les tachykinines pouvait indirectement inhiber d’autres interneurones. La substance P 
provoquait une augmentation de fréquence des CPSIs dans 2/3 des interneurones testés. 
En utilisant des agonistes spécifiques des récepteurs aux tachykinines, nous avons pu 
montrer que cet effet était dû à des récepteurs de type NK1. Contrairement à la substance 
P, l’ocytocine, un autre peptide capable d’activer les interneurones de l’hippocampe, n’avait 
pas d’effet sur l’input inhibiteur. Nous concluons que les tachykinines peuvent influencer le 
 
 
fonctionnement de l’hippocampe en inhibant indirectement les cellules pyramidales mais 
aussi d’autres interneurones inhibiteurs. Selon la balance précise entre ces effets, les 
tachykinines peuvent promouvoir soit l’activation, soit la dépression de l’hippocampe.  
 
 
 
III. General introduction 
Substance P and other tachykinins 
The undecapeptide substance P (SP) was the first identified neuroactive peptide. In 1931, 
Von Euler characterized this peptide as an “unidentified depressor substance” in extracts of 
horse brain and intestine (Von Euler, 1931). This substance caused transient hypotension 
when injected systemically and stimulated the contraction of intestinal tissues in vitro. In 
1934, Gaddum and Schild introduced the term “substance P” referring to a concentrate of 
the active principle in the form of a stable dry powder (Gaddum, 1934).  
 
SP belongs to a family of neuropeptides called tachykinins which share the common C-
terminal amino acid sequence Phe-X-Gly-Leu-Met-NH2. SP is encoded by the 
preprotachykinin-A (PPT-A) gene (Carter, 1992). Transcription of the PPT-A gene 
generates, by alternate splicing, four different tachykinins: SP, neurokinin A (NKA) and its N-
terminally extended forms neuropeptide γ (NPγ) and neuropeptide K (NPK). Neurokinin B 
(NKB) is a tachykinin derived from a second gene, the preprotachykinin-B (PPT-B) gene. 
PPT-C is a third gene recently identified that gives rise, again by alternative splicing, to five 
different tachykinins: hemokinin 1 (HK-1) and its N-terminally extended forms endokinins A 
and B (EKA and EKB), endokinin C (EKC) and endokinin D (EKD) (Page et al., 2003). 
Whereas SP, NKA and NKB are widely expressed in the central nervous system, hemokinin-
1 and endokinins are primarily expressed in non-neuronal cells.  
 
SP frequently co-localizes in the same neuron with other neurokinins and with “classical” 
transmitters such as dopamine, acetylcholine, serotonin, GABA and glutamate. Furthermore, 
 
 
SP closely interacts with these transmitters by regulating their release and/or inhibiting or 
enhancing their effects (for a review, Suzue et al., 1981). 
 
H - Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met - NH+ 
 
Fig.1: Aminoacid sequence of the undecapeptide substance P 
 
 
Tachykinin receptors 
Tachykinin receptors are classified as NK1, NK2 and NK3 receptor subtypes (NK1R, NK2R 
and NK3R respectively) based on whether they bind preferentially SP, neurokinin A or 
neurokinin B respectively (Regoli et al., 1994). Tachykinin receptors belong to the G protein-
coupled receptor family. While NK1 and NK3 binding sites and receptor mRNAs are present 
throughout the mammalian brain, binding sites for NK2 receptors have been described only 
recently and had a weak density when compared with those of NK1 and NK3 binding sites 
(Saffroy et al., 2003). In the central nervous system, tachykinin receptors participate in 
several regulatory functions. For example, tachykinin receptors play a role in pain 
transmission in the spinal cord and in cardiovascular and respiratory regulation and emesis 
in the brainstem. Moreover, tachykinin receptors present in neurons located in the amygdala 
or related brain areas probably play a role in anxiety and depression (Quartara and Maggi, 
1998; Rupniak and Kramer, 1999; Rosaria Melis et al., 2000; Hill, 2002). Other possible 
functions of central tachykinin receptors will be described below. 
 
 
Substance P and tachykinin receptors in the hippocampus 
The hippocampus is richly innervated by SP-containing axons (Borhegyi and Leranth, 1997). 
This SP innervation probably originates from GABAergic interneurons in the hippocampus 
itself and from neurons located in the supramammillary area. GABAergic interneurons 
present in all hippocampal subfields (dentate gyrus, hilus of the dentate gyrus, CA3, CA1) 
possess SP receptors as detected by immunohistochemistry (Acsady et al., 1997; Sloviter et 
al., 2001). These receptors are mainly of the NK1 and NK3 type (Saffroy et al., 2003). NK1R 
co-localize with parvalbumin, a marker of interneurons innervating the perisomatic region of 
pyramidal cells, with calbindin, a marker typical of interneurons innervating the dendritic 
region of pyramidal cells, and with calretinin, a marker of interneurons specialized to 
innervate other interneurons. Principal cells, i.e. dentate granule cells, hilary mossy cells and 
hippocampal pyramidal cells, appear to be devoid of SPR-like immunoreactivity (Sloviter et 
al., 2001). Autoradiographic studies confirm the presence of both NK2R and NK3R in the 
hippocampus (Saffroy et al., 2001, 2003). 
 
 
 
 
 
 
 
Fig. 2: (Left) SP-immunoreactive neurons in the hippocampus (arrows and arrowheads) (from 
Borhegyi et Leranth, J Comp Neurol, 1997). (Right) SP receptor-like immunoreactivity (from 
Sloviter et al, J Comp Neurol, 2001) 
 
 
 
Electrophysiological studies in the hippocampus 
In the hippocampus, SP modulates the activity of both principal cells and interneurons. In 
pyramidal cells of mice, SP reduces the CA1 field potential (evoked by electrical stimulation 
of Schaffer’s collaterals) and the amplitude of evoked excitatory and inhibitory post-synaptic 
potentials (Kouznetsova and Nistri, 1998). SP also increases the inhibitory synaptic input on 
pyramidal neurons in the rat (Ogier and Raggenbass, 2003). SP has only slight effects on 
membrane potential of principal cells but facilitates cholinergic transmission in the mouse as 
SP application largely enhances the membrane depolarisation and oscillatory activity 
induced by a cholinergic agonist (Kouznetsova and Nistri, 2000). Finally, SP enhances N-
methyl-D-aspartate (NMDA) channel function in hippocampal dentate gyrus granule cells of 
the rat (Lieberman and Mody, 1998). SP also powerfully excite hippocampal interneurons 
(Dreifuss and Kelly, 1972; Ogier and Raggenbass, 2003). By increasing the excitability of 
CA1 GABAergic interneurons, SP facilitates the inhibitory synaptic input to pyramidal 
neurons as well as to other interneurons (chapter VI). In all these experiments, the effect of 
SP was mainly mediated by tachykinin receptors of the NK1 type. For this reason, and 
because this type of receptor is the most widely distributed in the CNS, we will focus on 
NK1R subtype in this introduction. 
 
 
 
Functional and pathological role of central substance P in the hippocampus 
Epilepsy. Seizure activity causes pronounced region-specific changes in expression of 
virtually every neuropeptide in the hippocampal formation (Schwarzer et al., 1996; Gallezot 
et al., 2005). In the human, the number of SPergic neurons is greatly reduced in the 
hippocampus of patients suffering from temporal lobe epilepsy (de Lanerolle et al., 1992).  
In the rat, intrahippocampal administration of SP triggers self-sustaining status epilepticus in 
response to stimulation of the perforant path for periods too brief to have any effect in 
control rats. This status epilepticus generates a pattern of acute hippocampal damage 
resembling that occurring in human epilepsy (Liu et al., 1999a). This effect can be blocked 
by NK1R antagonists. In addition, during the course of status epilepticus, the expression of 
hippocampal preprotachykinin A (a precursor of SP) mRNA and SP is dramatically 
increased in principal neurons (Liu et al., 1999a). Kainic acid administration – a well-known 
model for epilepsy (Sperk, 1994) – also increases the preprotachykinin-A mRNA level in the 
rat hippocampus (Brene et al., 1992). Mice lacking the preprotachykinin A gene are resistant 
to kainate-induced seizures and neuronal death (Liu et al., 1999b). SP also increases 
glutamate release from hippocampal slices (Liu et al., 1999a). Taken together, these results 
suggest that SP may participate to both the initiation and the maintenance of seizures.  
Antagonists of tachykinin receptors should thus constitute a novel category of drugs in 
antiepileptic therapy. To date, however, no report describing a clinical use of tachykinin 
receptor antagonists for this purpose has been published. 
 
Memory and learning. The hippocampus is involved in many learning and memory 
processes. Moreover, SP given systemically or intracerebrally shows a memory-promoting 
and reinforcing effect in rats (reviewed in Hasenohrl et al., 2000). Neuropeptide K and 
neurokinin A facilitate learning after local injections into the hippocampus (Flood et al., 
 
 
1990). SP has excitatory effects in the guinea pig hippocampus and is able to facilitate LTP 
via activation of the NK1R (Langosch et al., 2005). Finally, a NK1R antagonist (SR140333) 
enhances ACh level – a neuromodulator known to influence learning and memory processes 
– in the rat hippocampus in vivo (Kart et al., 2004). These results suggest a role of SP and 
of the NK1R in learning and memory formation. Surprisingly, the NK1R-/- genotype has only 
a weak  influence on hippocampus-dependent learning and memory tasks (Morcuende et 
al., 2003). Thus far, the clinical use of SP or NK1 receptors agonists as memory and 
learning promoting agents has not been investigated. 
 
Depression and anxiety. In 1998, Kramer and Rupniak reported that a selective NK1 
receptor antagonist was an effective and well-tolerated antidepressant in a placebo and 
active controlled (paroxetin) study (Kitagawa et al., 2003). This has stimulated research into 
the function of SP and the NK1R in depression and anxiety and the possible use of SP 
antagonists in the treatment of these disorders. Both genetic disruption and acute 
pharmacological blockade of the NK1R in mice result in a marked reduction of anxiety and 
stress-related responses (Santarelli et al., 2001). Mice with disruption of the neurokinin-1 
receptor gene (NK1R-/-) behave similarly in assays relevant to depression and anxiety 
(resident-intruder and forced swim tests) to rodents treated chronically with established 
antidepressants (Rupniak et al., 2001; Santarelli et al., 2001). Disruption or blockade of the 
NK1R may generate antidepressant-like effects in part by modulating monoamine 
transmission in cortical and hippocampal areas (Breedlove et al., 1982; Chen and Patrick, 
1997; Santarelli et al., 2001; Kulkarni et al., 2002). The NK1R is widely distributed 
throughout the brain, particularly in subcortical areas and areas of the midbrain associated 
with reward and motivation (Nakaya et al., 1994). It is therefore possible that NK1R 
disruption or antagonism modulate mood through both monoaminergic and 
nonmonoaminergic pathways. Indeed, activity at many sites throughout the brain may 
 
 
contribute to the reduced side-effect profile (such as lesser sexual dysfunction) reported in 
depressed patients treated with NK1 antagonists when compared to selective serotonin 
reuptake inhibitors such as paroxetin (Kitagawa et al., 2003).  Thus far however, the clinical 
studies are a mixture of positive, inconclusive and negative studies on the antidepressant 
activity of NK1R antagonists (McLean, 2005). One explanation could be that blockade of the 
NK1R alone might not be sufficient to produce consistent anxiolytic and antidepressant 
effects. Of special interest might be antagonists that, in addition to blocking NK1R, also 
block NK2R and/or NK3R (Herpfer and Lieb, 2005). 
 
 
 
Other roles for central substance P 
Nausea and vomiting.  Aprepitant (Emend®) is the first – and so far the only – 
commercially available drug of the tachykinin non-peptide antagonist family. Oral aprepitant, 
in combination with other agents, is indicated for the prevention of acute and delayed 
chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic 
chemotherapy in adults. When added to standard therapy (a serotonin 5-HT3 receptor 
antagonist and a corticosteroid), aprepitant is effective and generally well tolerated in the 
prevention of CINV (Dando and Perry, 2004). This compound exerts its effect by acting on 
central nervous system targets. Aprepitant is available in Switzerland (Compendium, 2005). 
 
Pain. A wealth of preclinical data suggests that NK1R antagonists might be useful for the 
treatment of pain. However, clinical trials have now shown that drugs that block the actions 
of substance P by acting as antagonists at the NK1 receptor fail to produce analgesia in a 
variety of clinical pain states (reviewed and discussed in Hill, 2000; Kesingland et al., 2000). 
This is both surprising and disappointing. On dorsal-horn spinal neuron – where SP has 
excitatory effect – blockade of SPergic transmission might not be sufficient because many 
other neuropeptides and classic transmitters – most importantly glutamate – are released 
concomitantly from the sensory nerve endings. 
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IV. Introduction to the work 
The hippocampus contains principal neurons, i.e. pyramidal cells, which are glutamatergic 
and project to a variety of other brain regions, and interneurons, which are GABAergic and 
project locally. A single interneuron can synapse with numerous pyramidal cells, as well as 
with other interneurons, and can thus regulate the activity of a large neuronal population 
(Freund & Buzsaki, 1996). In contrast to pyramidal cells, which constitute a relatively uniform 
population, interneurons appear to be highly heterogeneous, both in their morphology and in 
their physiological and pharmacological properties (Maccaferri & Lacaille, 2003; Monyer & 
Markram, 2004; Mott & Dingledine, 2003). In spite of these complexities, hippocampal 
interneurons have been tentatively classified in three families, based on their termination 
pattern and calcium-binding protein content (Freund & Buzsaki, 1996): i) Basket and 
chandelier interneurons, which innervate the soma and axon initial segments of pyramidal 
cells and which are mainly immunoreactive for parvalbumin. ii) Dendritic inhibitory 
interneurons, which innervate the dendritic tree of pyramidal cells and which are at least in 
part immunoreactive for calbindin. iii) Interneurons innervating other interneurons, which are 
calretinin-immunoreactive. 
 
Inhibitory interactions between hippocampal GABAergic interneurons and pyramidal cells 
have been extensively investigated. Less is known concerning inhibitory interactions 
between interneurons. Hippocampal interneurons possess GABAA receptors probably 
formed by a variety of combinations of α, β and γ subunits (Gao & Fritschy, 1994; 
Patenaude et al., 2001). GABAergic synapses of interneurons display activity-dependent 
plasticity distinct from that of pyramidal cells (Patenaude et al., 2005). The inhibitory input to 
interneurons can be facilitated by glutamate, an effect mediated by presynaptic kainate 
 
 
receptors (Cossart et al., 2001). By contrast, activation of presynaptic metabotropic 
glutamate receptors (group III) can depress IPSCs (Kogo et al., 2004). Functionally, 
inhibitory interactions between subclasses of interneurons may contribute to the generation 
of hippocampal theta and gamma rhythms (Banks et al., 2000; Bartos et al., 2002; White et 
al., 2000; Whittington et al., 1995). 
 
The hippocampus is innervated by substance P-containing axon terminals (Borhegyi & 
Leranth, 1997) and hippocampal GABAergic interneurons possess tachykinin receptors 
(Acsady et al., 1997; Sloviter et al., 2001). Peptides of the tachykinin family can powerfully 
excite hippocampal interneurons (Dreifuss & Raggenbass, 1986; Zaninetti & Raggenbass, 
2000), an action which is mediated by NK1 receptors and is due to a peptide-induced 
suppression of a resting K+ conductance (Ogier & Raggenbass, 2003). By exciting 
hippocampal interneurons, tachykinins enhance the frequency of spontaneous inhibitory 
events in principal cells, causing an indirect inhibition of these neurons (Ogier & 
Raggenbass, 2003). Due to the existence of interneuron-interneuron synapses, however, 
tachykinins may also indirectly inhibit other interneurons, leading to a partial disinhibition of 
principal cells. The aim of the present work was twofold. i) To directly demonstrate that 
tachykinin-induced action potentials can generate monosynaptic IPSCs in pyramidal cells. ii) 
To determine whether tachykinins can indirectly inhibit other interneurons. Recordings were 
performed in acute hippocampal slices using the whole-cell patch clamp technique. 
 
 
V. Materials and methods 
Hippocampal slices 
The animals used were 2-3-week-old rats of the Sprague-Dawley strain (Charles River 
Laboratories, Iffa Credo, L’Arbresle, France). They were anesthetized (pentobarbital i.p., 50 
mg/kg) and sacrificed by decapitation in accordance with the rules of the Swiss Federal 
Veterinary Office. The brain was removed and a block of tissue containing the dorsal part of 
the hippocampus was prepared. Coronal slices, 300-400-μm-thick, were cut using a 
vibrating microtome (Campden Instruments, Leicester, UK). A slice was transferred to 
thermoregulated (32-33 oC) recording chamber and perfused with a solution containing (in 
mM): NaCl, 135; NaHCO3, 15; KCl, 5; MgCl2, 1; CaCl2, 2; glucose 10; and saturated with 
95% O2/5% CO2 (pH7.3-7.4). Neurons were visualized using a Nikon Eclipse E600FN, 
equipped with 40x0.8 NA water-immersion objective and DIC optics, and an infrared-
sensitive videocamera (C 25400-07, Hamamatsu, Schüpfen, Switzerland). In order to isolate 
GABAergic inhibitory synaptic currents (IPSCs), the perfusion solution was supplemented 
with 6-nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione disodium (NBQX; 5 μM) and MK801 
(20 μM).  
 
Electrophysiological recordings 
Whole-cell recordings were performed in neurons located in the CA1 region using patch 
pipettes pulled from borosilicate glass capillaries (Harvard Apparatus, Les Ulis, France). To 
monitor synaptic activity, in either pyramidal cells or interneurons, patch pipettes were filled 
with the following solution (mM): CsCl, 150; HEPES, 10; MgCl2, 4; 1,2,-bis(2-
aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA), 0.1; QX-314, 1; Na2-ATP, 2; Na2-
 
 
GTP, 0.4 (pH 7.2-7.3, adjusted with NaOH). In some experiments, the pipette solution also 
contained 1 mM QX-314. In dual recordings, presynaptic neurons were recorded with 
pipettes filled with a solution in which CsCl was substituted with 140 mM K-gluconate and 10 
mM KCl. For these pipette solutions, the calculated liquid junction potentials were 7.3 and 
14.9 mV, respectively (Clampex Junction Potential Calculator; pClamp software). The 
pipette resistance was 2-5 MΩ. Current signals, recorded in the voltage clamp, were 
amplified, digitized and acquired using an Axopatch 200A amplifier, a Digidata 1200 
interface and pClamp software (Molecular Devices, Sunnyvale, CA, USA). Current signals 
were low-pass filtered online at 2 kHz and digitized at 10 kHz. For dual recordings, the 
presynaptic neuron was recorded in the current clamp mode using an Axoclamp-2A 
(Molecular Devices). Synaptic events were detected using the Mini Analysis package 
(Synaptosoft, Decatur, GA, USA). The threshold current was set to10-20 pA and the 
threshold charge transfer to 30-60 fC. The detected events were visually inspected and 
contaminating noise events were rejected. Rise time was 10-90% and decay time was 
measured from the peak by fitting with a single exponential. For inhibitory synaptic currents 
(IPSCs), interevent intervals were distributed exponentially or approximately exponentially. 
Their average and spread are expressed as mean and 95% confidence interval. The 
amplitudes of IPSCs were distributed lognormally (Ogier & Raggenbass, 2003; Zaninetti & 
Raggenbass, 2000). The mean μ and the standard deviation σ of amplitudes were 
computed using the following equations: 
μ=exp(M+S2/2) and 
σ2=exp(2M+2S2)-exp(2M+S2), 
where M and S are the mean and the standard deviation of the normally distributed log-
transformed amplitudes. For normally or lognormally distributed samples, average value and 
 
 
spread are given as mean±SEM. The significance of the effect was evaluated using the 
Kolmogorov-Smirnov test or the Wilcoxon rank-sum test. 
 
Chemical compounds 
Substance P, (sar9,met(O2)11)-substance P (sar9-substance P), (β-ala8)-neurokinin A(4-10) 
(β-ala-NKA) and succinyl-(asp6,N-me-phe8)-substance P(6-11) (senktide) were purchased 
from Bachem (Bubendorf, Switzerland; for reviews on agonists and antagonists of tachykinin 
receptors, see (Regoli et al., 1994; Regoli et al., 1988)). The effects of these compounds 
were tested by adding them to the perfusion solution, except in some experiments in which 
substance P was applied locally by pressure ejection from a patch-type pipette positioned in 
the vicinity of the recorded neuron (10-20 psi, 50-200 ms). 6-nitro-7-
sulphamoylbenzo[f]quinoxaline-2,3-dione disodium (NBQX) and (+)MK 801 were from Tocris 
Cookson (Bristol, UK). QX-314 was from Alomone Labs (Jerusalem, Israel). 
 
 
VI. Results 
Dual recordings from interneuron-pyramidal cell pairs 
By acting on NK1 tachykinin receptors, substance P can powerfully excite CA1 hippocampal 
GABAergic interneurons (Dreifuss & Raggenbass, 1986; Ogier & Raggenbass, 2003; 
Zaninetti & Raggenbass, 2000) and this, in turn, causes indirect inhibition of CA1 pyramidal 
cells (Ogier & Raggenbass, 2003). To directly demonstrate that tachykinin-induced action 
potentials in interneurons can generate monosynaptic IPSCs in pyramidal cells, 
simultaneous whole-cell recordings from pairs of interneuron/pyramidal cell were attempted. 
A stratum radiatum interneuron was recorded in current-clamp using K-gluconate-containing 
patch pipettes, while a nearby pyramidal cell was recorded in voltage-clamp using CsCl-
containing patch pipettes. Synaptic connection between the pair of neurons was tested by 
checking the temporal correlation between a current-evoked presynaptic spike and ensuing 
postsynaptic IPSCs (Fig. 1A).  
 
In a first series of experiments, 11 pairs were examined. Only two were found to be 
synaptically connected. The effect of substance P was tested on one pair. The peptide, 
added to the perfusion solution (0.5 μM) depolarized the interneuron and elicited action 
potential firing (peak frequency, 5 Hz). Concomitantly, it induced an increase in the 
frequency and amplitude of spontaneous IPSCs in the pyramidal cell (Fig. 1B). Close 
inspection of voltage and current traces revealed that 21 out of the 41 action potentials 
evoked by substance P in the interneuron generated a corresponding IPSC in the pyramidal 
cell (Fig. 1C). The average synaptic latency, measured from the peak of the action potential 
to the beginning of the IPSC, was 1.5±0.1 ms. This latency is similar to that measured for a 
current-evoked action potential, which was about 1.5 ms (Fig. 1A). The parameters of the 
 
 
action potential-corresponding IPSCs could be reliably measured in a sample of 12 synaptic 
events. The IPSC amplitude was 37±2 pA (range, 25-50 pA), the rise time 1.5±0.1 ms 
(range, 1.2-2 ms) and the decay time 11.8±1.3 ms (range, 5.3-20 ms). The data suggest that 
in this case the IPSCs were generated at relatively few synaptic locations.  
 
The presence in the hippocampus of silent excitatory synapses has been reported by 
several groups (for reviews, see (Isaac, 2003; Malinow et al., 2000; Voronin & Cherubini, 
2004)). Recent data suggest that silent inhibitory synapses may also exist (Bekkers, 2005; 
Caillard et al., 1999; Gubellini et al., 2001; Kannenberg et al., 1999; Oda et al., 1995). We 
asked whether substance P could possibly result in the activation of otherwise silent 
GABAergic synapses on pyramidal cells. The effect of substance P, bath-applied at 0.5 μM, 
was tested on five of the unconnected pairs of interneuron/pyramidal cell mentioned above. 
Substance P excited all five interneurons and enhanced inhibitory synaptic transmission in 
all corresponding pyramidal cells. In the presence of the peptide, the interneurons – which 
were all silent in control conditions - discharged at 11.6±2.2 Hz (range, 5-18 Hz). In the 
pyramidal cells, the IPSC interval decreased, on average, from 106±18 ms (range, 50-150 
ms) to 37±7 ms (range, 22-51 ms) and the IPSC amplitude increased from 41±6 pA (range, 
28-57 pA) to 87±12 pA (range, 56-123 pA; P<0.01 in all cases). In spite of these effects, we 
could find no evidence for a peptide-dependent appearance of action potential-
corresponding IPSCs in any of the pyramidal cell. Thus, the indirect inhibition of pyramidal 
cells was due to a substance P-induced excitation of interneurons distinct from those 
present in the recorded pair. 
 
In a second series of experiments, four pairs of interneuron/pyramidal cell – none of which 
appeared to be synaptically connected – were recorded and substance P was locally applied 
to the interneuron by pressure ejection. The four interneurons, which were all silent in 
 
 
control conditions, were excited by substance P (0.2-2 µM). The peak frequency of 
discharge attained 19.5±3.3 Hz (range, 12-25 Hz). In two out of the four pyramidal cells, 
inhibitory synaptic transmission was enhanced. The IPSC interval decreased, on average, 
from 67±12 ms to 35±8 ms and the IPSC amplitude increased from 53±9 pA to 77±24 
(P<0.05 in all cases). Again, we could find no evidence for a peptide-induced appearance of 
action potential-corresponding IPSCs in these two cells. Incidentally, these data indicate 
that, in two out of four instances, local application of the peptide to a visually identified 
interneuron could also excite unidentified interneuron(s) located in its proximity and making 
synaptic contacts with the recorded pyramidal cells. Thus, caution should be exerted in 
interpreting data obtained in brain slices following “local application” of an agonist. 
 
Tachykinins enhance the inhibitory input to CA1 interneurons 
In addition to inhibitory interneurons innervating the soma or the dendritic tree of pyramidal 
cells, the hippocampus contains interneurons which selectively innervate other interneurons 
(Freund & Buzsaki, 1996). We asked whether tachykinins, by exciting interneurons of this 
type, could cause an indirect inhibition of at least a subpopulation of interneurons. Whole-
cell recordings were performed in CA1 interneurons located in stratum radiatum using CsCl-
containing patch pipettes. Under these recording conditions, the average cell input 
resistance was 276±30 MΩ (n=39) and IPSCs appeared as inward-going currents. 
Substance P, added to the perfusion solution at concentrations ranging from 0.1 µM to 1 
µM, increased the frequency, and in some cases also the amplitude, of spontaneous IPSCs 
in a majority of the interneurons tested (14 out of 21 neurons; Fig. 2A). When present, this 
effect was reversible and reproducible and tachyphilaxis was not observed.  
 
 
 
The charge carried by the substance P-induced synaptic inhibition was about three times 
larger than that transferred during basal inhibitory activity. Indeed, the average inhibitory 
current was 12±4 pA in control conditions and 34±4 pA in the presence of the peptide (n=5; 
measured over a 2-s interval; Fig. 3). 
 
The effect of Substance P on IPSCs was quantified in 12 interneurons. Substance P caused 
a decrease in the mean IPSC interval in all 12 neurons and an increase in the IPSC 
amplitude in 9 of them (P<0.001 in all cases; Fig. 4). In control conditions, the mean IPSC 
interval was 141±26 ms (range, 53-303 ms), whereas in the presence of substance P it was 
47±7 ms (range, 28-102 ms). The mean IPSC amplitude was 38±5 pA in control conditions 
(range, 17-65 pA) and 60±6 pA in the presence of the neuropeptide (range, 23-87 pA). 
Thus, on the whole, substance P caused a nearly three-fold increase in the IPSC frequency 
and a 60% increase in the IPSC amplitude. 
 
The rise time of spontaneous IPSCs ranged from 1.04 to 1.97 ms and was, on average, 
1.4±0.1 ms. Substance P did not alter the rise time in seven neurons, decreased it slightly in 
3 neurons (17%, 10% and 26%; P<0.01) and increased it slightly in 2 neurons (19% and 
17%; P<0.01) . The IPSC decay time ranged from 1.5 to 4.4 ms, with an average value of 
2.4±0.3 ms. It was unaffected by substance P in three neurons, was increased in 8 neurons 
(8-77%; P<0.01) and was decreased in one neuron (35%, P<0.01).  
 
Miniature, action potential-independent IPSCs (mIPSCs) were recorded in CA1 interneurons 
in the presence of TTX (1 µM). Four neurons were examined. The mean mIPSC interval 
was 213±64 ms (range, 80-389 ms) and the mean mIPSC amplitude was 31±2 pA (range, 
26-35 pA; Fig. 4). Substance P (1 µM) did not affect either the interval or the amplitude of 
mIPSCs in any of these neurons. The mIPSC rise time ranged from 1.4 to 1.6 ms, and was 
 
 
1.5±0.1 ms on average. The decay time was 2.6-3.2 ms and was 2.7±0.2 ms on average. 
Neither the rise time nor the decay time were effected by substance P in any of these 
neurons. The decay time of interneuron mIPSCs was much faster that that of mIPSCs in 
pyramidal cells, which was 10±1.2 ms (Ogier & Raggenbass, 2003); see also (Hajos & 
Mody, 1997; Nusser et al., 2001).  
 
Pharmacology of the tachykinin action 
The pharmacological profile of the receptors responsible for the facilitatory effect of 
substance P on interneuron IPSCs was determined by making use of selective agonists and 
antagonist of tachykinin receptors. Neither β-ala-NKA (0.1-1 µM; n=5) nor senktide (0.1-1 
µM; n=5), agonists of NK2 and NK3 receptors respectively, could mimic the effect of 
substance P on the IPSC frequency or amplitude (Fig. 5). By contrast, the facilitatory effect 
of substance P on IPSCs could be mimicked by (sar9,met(O2)11)-substance P (0.1-1 µM; 
n=4), a NK1 receptor agonist, and could be suppressed by SR 140333 (1 µM; n=2), a NK1 
receptor antagonist (Fig. 6). Thus, substance P enhanced inhibitory transmission in 
hippocampal interneurons by acting on NK1 receptors. 
 
Effect of oxytocin on interneuron IPSCs 
It has been previously shown that oxytocin receptor agonists can stimulate inhibitory 
synaptic transmission in CA1 pyramidal cells by activating interneurons located in stratum 
pyramidale (Zaninetti & Raggenbass, 2000). We tested whether these compounds also 
facilitated IPSCs in CA1 interneurons. We found that oxytocin, added to the perfusion 
solution at concentrations ranging from 0.5 µM to 1 µM, did not alter the frequency or the 
amplitude of IPSCs in 8 out of 8 interneurons. 
 
 
VII. Figures 
Figure 1 
Effect of substance P on a pair of hippocampal interneuron and pyramidal cell. (A) 
Presynaptic action potentials evoked in a CA1 interneuron by a short depolarizing current 
pulse (top trace; average of 20 trials) and corresponding postsynaptic IPSCs recorded in an 
adjacent, synaptically coupled pyramidal cell (bottom trace; average of 20 trials). Note that 
the synaptic latency, measured from the peak of the action potential to the beginning of the 
IPSC, was about 1.5 ms. Note also that the second IPSC was slightly facilitated with respect 
to the first one. (B) Action potential discharge evoked by substance P in the interneuron (top 
trace) and concomitant peptide-induced enhancement of IPSCs in the pyramidal cell (bottom 
trace). Substance P (0.5 μM) was present in the perfusion solution for the time indicated by 
the horizontal bar. (C) Detail of the traces illustrated in B, and showing that, during the 
substance P effect, two out of three peptide-evoked presynaptic action potentials (bottom 
trace) generated postsynaptic IPSCs (top trace).  
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Figure 2 
Effect of substance P on the frequency and amplitude of spontaneous IPSCs in a 
hippocampal CA1 interneuron. (A) Each panel shows four consecutive current traces 
recorded in the voltage-clamp configuration in the normal perfusion solution (control), in the 
presence of substance P (SP; 1 μM) and following washout of the peptide (recovery). (B, top 
panel) Cumulative plot of the IPSC interval distribution in control conditions (continuous line; 
n=195) and in the presence of substance P (dotted line; n=320). (B, bottom panel) 
Cumulative plot of the IPSC amplitude distribution in control conditions (continuous line) and 
in the presence of substance P (dotted line). Note that in the presence of the peptide, the 
IPSC interval distribution shifted towards smaller values, whereas the IPSC amplitude 
distribution shifted in the opposite direction.  
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Figure 3 
Effect of substance P on the average inhibitory current in a hippocampal CA1 interneuron. 
The average inhibitory current was computed in control conditions (top panel) and in the 
presence of substance P (SP; 1 μM; bottom panel), by subtracting the baseline current 
(continuous line) from the average current generated by spontaneous IPSCs (dashed line). 
Note that substance P caused a three-fold increase in the average inhibitory current, from 
11 to 30 pA.  
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Figure 4 
Effect of substance P on the frequency and amplitude of spontaneous IPSCs and mIPSCs 
in a hippocampal CA1 interneuron. (A) Current traces recorded in voltage-clamp in the 
normal perfusion solution (control), in the presence of substance P (SP; 1 μM), following 
addition of TTX (1 μM) to the perfusion solution and in the presence of both TTX and 
substance P. (B, top panels) Cumulative plots of spontaneous IPSC interval and amplitude 
distribution in control conditions (continuous line; n=65) and in the presence of substance P 
(dotted line; n=493). (B, bottom panels) Cumulative plots of mIPSC interval and amplitude 
distribution in control conditions (continuous line; n=150) and in the presence of substance P 
(dotted line; n=122). Note that substance P facilitated spontaneous IPSCs but not mIPSCs.  
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Figure 5 
Effect of substance P and of NK2 and NK3 receptor agonists on the frequency and 
amplitude of spontaneous IPSCs in a hippocampal CA1 interneuron. The cumulative plots of 
spontaneous IPSC interval (A) and amplitude (B) distribution were obtained in control 
conditions (continuous lines; n=120, 152 and 110, respectively) and in the presence of the 
following compounds (dotted lines): substance P (SP; 0.1 μM, n=283), (β-ala8)-neurokinin 
A(4-10) (β-ala-NKA; 0.1 μM; n=138) and senktide (0.1 μM; n=118). Note that, contrary to 
substance P, the NK2 and NK3 receptor agonists did not affect the frequency or amplitude 
of spontaneous IPSCs.  
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Figure 6 
Effect of a NK1 receptor agonist, of substance P and of a NK1 receptor antagonist on the 
frequency and amplitude of spontaneous IPSCs in a hippocampal CA1 interneuron. The 
cumulative plots of spontaneous IPSC interval (A) and amplitude (B) distribution were 
obtained in control conditions (continuous lines, n=186, 174 and 180, respectively) and in 
the presence of the following compounds (dotted lines): (sar9,met(O2)11)-substance P 
(σαρ9−ΣΠ; 1 μM; n=311), substance P (SP; 1 μM; n=279) and SR 140333 and substance P 
(antag+SP; both at 1 μM; n=162). Note that the effect of substance P was mimicked by the 
NK1 receptor agonist and was suppressed by the NK1 receptor antagonist.  
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VIII. Discussion 
We have found that tachykinin-induced action potentials in stratum radiatum interneurons 
can generate monosynaptic IPSCs in CA1 pyramidal cells. This confirms that tachykinins 
can indirectly inhibit pyramidal cells (Ogier & Raggenbass, 2003), probably by exciting 
GABAergic interneurons which innervate the somatic or dendritic membrane of pyramidal 
cells (Freund & Buzsaki, 1996). We have also found that tachykinins can facilitate IPSCs in 
stratum radiatum interneurons, presumably by exciting GABAergic interneurons which 
selectively innervate other interneurons (Freund & Buzsaki, 1996). This suggests that, 
depending on the specific interneuronal population(s) they activate, tachykinins can either 
depress or disinhibit principal cell activity.  
 
In a first part of our study, we attempted to perform simultaneous dual recordings from pairs 
of interneuron/pyramidal cell. Of 15 pairs examined, only two were found to be synaptically 
connected, indicating that in our conditions the probability of finding connected pairs was 
about 0.13. Although in the present study the number of recorded pairs was limited, this 
figure compares with those reported by (Ali et al., 1999). These authors reported that in 
coronal hippocampal slices containing the CA1 region the probability of finding 
monosynaptically connected putative basket cells and pyramidal cells pairs varied as a 
function of their relative distance, being 0.5 for pairs separated by 50-100 μm and 0.05 for 
pairs separated by 150-200 μm. 
 
Tachykinins did not affect mIPSCs in hippocampal interneurons. Indeed, the tachykinin-
evoked increase in the frequency and amplitude of IPSCs in CA1 interneurons was 
suppressed by TTX. Thus, the peptide-facilitated IPSCs were action potential-dependent, 
 
 
i.e. were due to tachykinins acting on NK1 receptors located on the somatodendritic 
membrane of interneurons, rather than at their axon terminals. In addition to increase the 
frequency of spontaneous IPSCs, tachykinins also increased their amplitude. This may 
suggest that these compounds acted in part postsynaptically. However, the fact that the 
mIPSC amplitude was not modified by tachykinins argues against such a possibility. We 
suggest that the increase in the IPSCs amplitude was a consequence of the tachykinin-
induced increase in the IPSC frequency. This could be due to a frequency-dependent 
facilitation at GABAergic interneuron-interneuron synapses (Gupta et al., 2000; Markram et 
al., 1998). In conclusion, tachykinins appear to act exclusively at the level of the 
somatodendritic membrane of interneurons presynaptic to the recorded interneuron.  
 
The tachykinin-induced indirect inhibition of interneurons appears to be mediated by NK1, 
but not NK2 or NK3 receptors. Thus, interneurons that innervate other interneurons (which 
are calretinin-containing) possess the same type of tachykinin receptors than as the 
interneurons innervating pyramidal cells (Ogier & Raggenbass, 2003). Our 
electrophysiological data are in accordance with morphological data showing that virtually all 
the hippocampal interneurons which are immunoreactive for parvalbumin, calbindin or 
calretinin, as well as for neuropeptides such as somatostatin, neuropeptide Y, 
cholecystokinin or vasoactive intestinal peptide, express tachykinin receptors of the NK1 
type (Acsady et al., 1997; Sloviter et al., 2001).  
 
Tachykinins appear to play a critical role in the control of hippocampal excitability and 
seizures. Intrahippocampal administration of substance P, followed by perforant path 
stimulation, can induce and sustain a status epilepticus, and this effect can be blocked by a 
substance P antagonist (Liu et al., 1999b). In addition, mice lacking the preprotachykinin A 
gene, which encodes substance P, are resistant to kainate-induced seizures and 
 
 
excitotoxicity (Liu et al., 1999a). The seizure promoting effect of tachykinins may be 
explained as following. i) Due to possible differences in the intrinsic 
pharmacological/physiological properties of different types of interneurons, tachykinins could 
exert a more powerful effect on calretinin-containing interneurons than on parvalbumin- or 
calbinding- containing interneurons. This would cause a preferential inhibition of 
interneurons controlling pyramidal cells, thus leading to pyramidal cell dishinibition. ii) 
Alternatively, since virtually all hippocampal interneurons possess NK1 receptors, 
tachykinins can excite the whole interneuronal population. If the tachykinin concentration is 
sufficiently high, interneuron excitation could be so strong as to cause action potential 
inactivation, cessation of GABA release and pyramidal cell dishinibition. 
 
In a previous study, we found that the neuropeptide oxytocin can excite hippocampal CA1 
interneurons located in stratum pyramidale, causing an indirect inhibition of CA1 pyramidal 
cells (Zaninetti & Raggenbass, 2000). This effect is mediated by uterine-type oxytocin 
receptors. In the present study we tested whether oxytocin, by acting on hippocampal 
interneurons, could also inhibit other interneurons. Interestingly, at variance with what was 
found for tachykinins, oxytocin did not facilitate IPSCs in any of the recorded interneurons. 
 
Thus, tachykinins can influence the hippocampal activity by indirectly inhibiting both 
pyramidal cells and GABAergic interneurons. Depending on the precise balance between 
these effects, tachykinins may promote either activation or depression of the hippocampal 
network activity. This modulation could play a role in regulating short-term and/or long-term 
synaptic plasticity, promoting neuronal circuit oscillations or synchronization or, in some 
physiopathological situations, influencing epileptogenesis.  
 
 
Abbreviations 
BAPTA, 1,2,-bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid 
β-ala-NKA, (β-ala8)-neurokinin A(4-10) 
NBQX, 6-nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione disodium 
sar9-substance P, (sar9,met(O2)11)-substance P 
senktide, succinyl-(asp6,N-me-phe8)-substance P(6-11) 
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